Proton magnetic resonance spectroscopic creatine correlates with creatine transporter protein density in rat brain

Journal of Neuroscience Methods

Volumn 172, Issue 2, 2008, Pages 215-219

  Sartorius, Alexander ^a   Lugenbiel, Patrick ^a   Mahlstedt, Magdalena M ^a,b   Ende, Gabriele ^a   Schloss, Patrick ^a   Vollmayr, Barbara ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Brain; Creatine; Creatine transporter; Energy metabolism; Magnetic resonance spectroscopy; Phosphocreatine; Rat; Western blot

Indexed keywords

CREATINE; CREATINE PHOSPHATE; CREATINE TRANSPORTER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN CHEMISTRY; CEREBRUM; CREATINE; CREATININE; ENERGY METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE TRANSPORT PROTEINS; NEUROCHEMISTRY; NEURONS; PHOSPHOCREATINE; PROTONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 46249121586     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.04.028     Document Type: Article

References (36)

1. Bender A, Beckers J, Schneider I, Holter SM, Haack T, Ruthsatz T, et al. Creatine improves health and survival of mice. Neurobiol Aging 2007 [Epub ahead of print].
2. Carrey N.J., MacMaster F.P., Gaudet L., and Schmidt M.H. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17 (2007) 11-17
3. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 98 (2001) 12796-12801
4. Dechent P., Pouwels P.J., Wilken B., Hanefeld F., and Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 277 (1999) R698-R704
5. Ende G., Braus D.F., Walter S., Weber-Fahr W., and Henn F.A. The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry 57 (2000) 937-943
6. Ende G., Demirakca T., and Tost H. The biochemistry of dysfunctional emotions: proton MR spectroscopic findings in major depressive disorder. Prog Brain Res 156 (2006) 481-501
7. 1H-MRS at 3 Tesla. Invest Radiol 38 (2003) 403-408
8. Henn F.A., and Vollmayr B. Stress models of depression: forming genetically vulnerable strains. Neurosci Biobehav Rev 29 (2005) 799-804
9. Henn F.A., Vollmayr B., and Sartorius A. Mechanisms of depression: the role of neurogenesis. Drug Discov Today: Dis Mech 1 (2004) 407-411
10. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21 (2007) 1-11
11. Kato T., Kubota M., and Kasahara T. Animal models of bipolar disorder. Neurosci Biobehav Rev 31 (2007) 832-842
12. Kumar A., Thomas A., Lavretsky H., Yue K., Huda A., Curran J., et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry 159 (2002) 630-636
13. Lunardi G., Parodi A., Perasso L., Pohvozcheva A.V., Scarrone S., Adriano E., et al. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 142 (2006) 991-997
14. Lyoo I.K., Kong S.W., Sung S.M., Hirashima F., Parow A., Hennen J., et al. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 123 (2003) 87-100
15. Malhi G.S., Valenzuela M., Wen W., and Sachdev P. Magnetic resonance spectroscopy and its applications in psychiatry. Aust NZ J Psychiatry 36 (2002) 31-43
16. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., and Pfleiderer B. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33 (2003) 1277-1284
17. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., and Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 28 (2003) 720-725
18. Michaelis T., Wick M., Fujimori H., Matsumura A., and Frahm J. Proton MRS of oral creatine supplementation in rats. Cerebral metabolite concentrations and ischemic challenge. NMR Biomed 12 (1999) 309-314
19. Modrego P.J., Pina M.A., Fayed N., and Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20 (2006) 867-877
20. Ohtsuki S., Tachikawa M., Takanaga H., Shimizu H., Watanabe M., Hosoya K., et al. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab 22 (2002) 1327-1335
21. 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 17 (2002) 917-927
22. Pan J.W., and Takahashi K. Cerebral energetic effects of creatine supplementation in humans. Am J Physiol Regul Integr Comp Physiol 292 (2007) R1745-R1750
23. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, San Diego
24. Sartorius A., Henn F.A., and Ende G. Proton magnetic resonance spectroscopy as a monitoring tool for electroconvulsive therapy effects on the brain. Curr Psychiatry Rev 2 (2006) 39-49
25. Sartorius A., Mahlstedt M.M., Vollmayr B., Henn F.A., and Ende G. Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. Neuroreport 18 (2007) 1469-1473
26. Sartorius A., Vollmayr B., Neumann-Haefelin C., Ende G., Hoehn M., and Henn F.A. Specific creatine rise in learned helplessness induced by electroconvulsive shock treatment. Neuroreport 14 (2003) 2199-2201
27. Schloss P., Mayser W., and Betz H. The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. Biochem Biophys Res Commun 198 (1994) 637-645
28. Schulze A. Creatine deficiency syndromes. Mol Cell Biochem 244 (2003) 143-150
29. Snow R.J., and Murphy R.M. Creatine and the creatine transporter: a review. Mol Cell Biochem 224 (2001) 169-181
30. Speer O., Back N., Buerklen T., Brdiczka D., Koretsky A., Wallimann T., et al. Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. Biochem J 385 (2005) 445-450
31. Speer O., Neukomm L.J., Murphy R.M., Zanolla E., Schlattner U., Henry H., et al. Creatine transporters: a reappraisal. Mol Cell Biochem 256-257 (2004) 407-424
32. Tachikawa M., Fukaya M., Terasaki T., Ohtsuki S., and Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 20 (2004) 144-160
33. Tran T.T., Dai W., and Sarkar H.K. Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter. J Biol Chem 275 (2000) 35708-35714
34. Vollmayr B., and Henn F.A. Learned helplessness in the rat: improvements in validity and reliability. Brain Res Brain Res Protoc 8 (2001) 1-7
35. Vyssokikh M.Y., and Brdiczka D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim Pol 50 (2003) 389-404
36. 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 147 (2006) 1-25